Member Info for WeTookPelham

A mere morsel for our hungry souls please Scancell!

Https://www.evaluate.com/vantage/articles/news/trial-results/astrazeneca-and-daiichis-big-reveal-disappoints

IMO it's very strange just how under the radar Scancell/Modi are, considering Scancell also have their trial running at the same place, considering there has been some local press etc.

Almost makes me wonder if Scancell are avoiding mainstream exposure to the Modi trial in particular, mybe as it is full subscribed?

Agree CW, mentioned something similar the other day. They are "conversely" quiet for a reason IMO.

".. just doesn’t feel like the right time to be releasing really positive information to me "

Based on what exactly Jambioan? Is there ever a right or wrong time? If news is ready they really shouldn't be holding it back, should they?

@AlmasSzabo - thanks for the reminder. Perhaps news won't be so out of the blue after all.

Well I'll keep my fingers crossed still for news out of the blue 🤞

Https://www.theguardian.com/business/2023/jul/03/astrazeneca-stock-falls-lung-cancer-drug-trial-results

Agree C7, those on the trial and their loved ones clearly have other priorities, also I wonder if those on the trial/families even know or care that bio's such as Scancell can invested in.

It does however raise that old question about NDA's for those working at the hospital directly involved with the trial and patients?

Https://www.mdpi.com/1422-0067/24/13/10859

Intersting article, one more for science types I think so a summary would be much appreciated. But references the Modi-1 trial:

"...Since numerous trials have proven the safety and potential benefits of DC vaccines, these agents could positively contribute to OC treatment outcomes [216]. Conversely, Martin-Lluesma et al. [217] have suggested that in addition to dendritic cell vaccines, B cells and macrophages could become the next agents playing a crucial role in the development of novel anti-cancer vaccines [217]. Moreover, according to Brentville et al. [218], the Modi-1 peptide vaccine consisting of a combination of citrullinated vimentin and enolase peptides could be an effective vaccine in OC patients [218]."

By the recent blogger on the renal combi trial, 7 days ago:

"Hi. Nov 2021 I was diagnosed with metastatic ccRCC. 57mm tumour on the kidney and small lung mets. I started immunotherapy in Jan 2022. Lung mets now undetectable, kidney tumour 26mm. Because my kidney tumour has spread, the approach is immunotherapy and the kidneys left intact. I don't get the standard side effects of sickness, bowel issues. I've just started on a medical trial (modi-1) alongside nivolumab which has great results in mice!! "

So seeing a substantial reduction in kidney and lung mets(?) now undetectable. How much of this is down to Modi do we think? They are a recent addition to the trial i believe.

P.s. Mets?

Thanks chester18, an excellent summary.

RE "The next data readout from Scancell will IMO give huge clues to our future potential.". Yes that next Modi update will be significant one way or another!

My issue/question is that i find it a quite irratating that we see multi billion $ pre-clinical deals, yet here we with drugs in the clinic being trialled with very promising early signs. So what gives? Personally speaking I don't mind if a big pharma can not wait for the more deeper results and feels the need to jump on Scancell ASAP, even if it means the odd less billion here an there. What's the odd billion between friends after all.

But I guess this is my impatience also playing a factor here.

RE timing, I guess it depends just how desperate a big pharma is (or not) for Scancell's wares.

The recent and on going radio silence, the trip to bio23 etc. makes me wonder.

Typo - Thus not this*

"...Those epic deals in the £B's are always due to the perceived huge commercial potential."

But that I think is my point, pre clinical deals i.e. perceived huge commercial "potential", still go for $billions. Don't Scancell have an advantage/this increased potential here?

Just to add to my last post, a very key point, another key reason I stay invested is when you see the size of deals for mere pre-clinical drugs/ bio companies.

The reason I stay invested (rightly or wrongly), and the reason I add on the dips is that if I was a big pharma, I would definitely be looking at Scancell and their very impressive portfolio. So purely IMO I strongly believe there are multiple parties interested as we speak.

IMO If a big pharma was to buy out Scancell outright their portfolio would overnight become far more comprehensive and hugely promising. And just imagine the progress of development and trials with big pharma backing.

In fact as mentioned by others, Scancell has a portfolio that is arguably bigger and better that some medium/large pharma?

Yes, imagine being out of that just it before went stratospheric. You'd be crying into your cornflakes.

And yes the chart does have some striking similarities IMO.

Do you want to join? We all have cool embroidered leather jackets with "Team Ramp" written on the back, and a secret handshake.

Is it just me or do your posts make zero sense?